What Doctors Mean by Watchful Waiting

Why this matters

Being told to wait when symptoms are affecting daily life can feel dismissive. Understanding what watchful waiting actually involves, and what it should include, makes it possible to engage with the plan rather than feel sidelined by it.

What is watchful waiting

Watchful waiting isn’t ignoring symptoms or hoping problems will go away. Watchful waiting is active monitoring of a condition that doesn’t currently require treatment, with clear criteria for when intervention becomes necessary. It involves regular clinical review, periodic testing to track changes, clear communication about what would trigger treatment, and patient education on warning signs to look out for.

When watchful waiting is appropriate

Watchful waiting is used in a number of clinical situations:

• Self-limiting conditions. Some illnesses resolve without treatment within predictable timeframes. Intervening wouldn’t speed recovery and may introduce unnecessary side effects
• Conditions not yet meeting treatment thresholds. Before clear diagnostic or severity criteria are met, treatment may be ineffective or carry more risk than benefit
• Uncertain diagnosis. Observing how symptoms evolve often clarifies what is happening, particularly in early autoimmune disease, where tests may be normal before the condition fully declares itself
• Balancing harm versus benefit. When the disease is mild, the risks of treatment may outweigh the benefits. Monitoring defers intervention until the severity justifies the risk

What clinicians are watching for

During a watchful waiting period, clinicians are actively assessing several things. They look at whether symptoms are worsening, stable, or improving. They review what blood tests, imaging, or physical findings show. They consider whether functional impact is changing even if symptoms appear stable. They also watch for any complications that would shift the risk-benefit calculation toward treatment.

What good watchful waiting should include

A watchful waiting plan isn’t simply being told to come back if things get worse. It should include:

• A clear monitoring plan. How often reviews will happen, which tests will be repeated, and which symptoms to report immediately
• Patient education. Why monitoring has been chosen over treatment, what risks are being balanced, and what the natural history of the condition typically looks like
• Safety netting. Explicit instructions on when to seek urgent review rather than waiting for the next scheduled appointment
• Flexibility to escalate. If circumstances change, the plan should adapt accordingly

If any of these are missing, it’s reasonable to ask for them directly.

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

When to question the plan

If placed on a watchful waiting plan, but there’s no clear schedule for review, no defined symptoms that would trigger earlier action, or the situation feels more like dismissal than structured monitoring, it’s reasonable to raise this. A useful question to ask is: "What exactly are we watching for, how often will I be reviewed, and what would trigger treatment?" Watchful waiting should feel like an active plan with clear next steps.

What you could do

• Keep a symptom record during this period. Patterns over time are exactly what clinicians need to make the next decision
• Note any changes in functional impact, not just symptom severity. These can shift the clinical picture even when test results appear stable
• If symptoms worsen significantly, don’t wait for the next scheduled review. Contact the GP or specialist to reassess

References:

‘A decision model for the watch-and-wait strategy in systemic sclerosis-associated interstitial lung disease’ (2015) https://doi.org/10.1093/rheumatology/kev121

‘A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype’ (2021) https://doi.org/10.1007/s00384-020-03811-8

‘EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update’ (2020) https://doi.org/10.1136/annrheumdis-2019-216655

‘Too much medicine; too little care’ (2013) https://doi.org/10.1136/bmj.f4247